Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …

Background The combination of ivosidenib—an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …

Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and
limited treatment options. Here we provide a comprehensive census of the bone marrow …

Background Acute myeloid leukemia (AML) is a common leukemia subtype and has a poor
prognosis. The risk of AML is highly related to age. In the context of population aging, a …

Abstract The World Health Organization classification and definition of “myeloid sarcoma” is
imprecise and misleading. A more accurate term is “extramedullary acute myeloid leukemia …

In recent years, the lymphocyte-specific protein tyrosine kinase (Lck) has emerged as one of
the key molecules regulating T-cell functions. Studies using Lck knock-out mice or Lck …

Leukemia stem cells (LSCs) sustain the disease and contribute to relapse in acute myeloid
leukemia (AML). Therapies that ablate LSCs may increase the chance of eliminating this …

CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for
acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized …

The effective treatment of acute myeloid leukemia (AML) is very challenging. Due to the
immense heterogeneity of this disease, treating it using a “one size fits all” approach is …